QSBS for Life Sciences Founders: Section 1202 Basics and Pitfalls
The decision to structure as a C-corporation (C-corp) is common in the biotech sector, especially for firms seeking venture capital funding. VCs favor C-corporations because the structure protects them and provides various tax benefits, including the Qualified Small Business Stock (QSBS) exclusion under Section 1202 of the federal tax code.
The QSBS may allow early investors and founders to exclude up to $10 million in capital gains (equivalent to 10x basis) from their federal returns when selling the stock at exit, if certain conditions are met,. Considering the growth potential of biotech, diagnostics, and medical devices, the move could translate to substantial savings.
Qualifying for QSBS hinges on specific technical requirements, plus structural decisions made when the company is established. Understanding the ins and outs of Section 1202 may help founders make informed decisions for their future and the company’s.
Unpacking Section 1202
Section 1202 incentivizes startup investment by enabling investors to exclude capital gains on qualified stock from their federal income tax return when they sell the shares.
In some cases, the exclusion can be up to 100% of the gain, capped at $10 million or 10 times the investor’s basis in the stock, whichever is greater. Certain conditions apply:
Shares must come from a domestic C-corp. LLCs and S-corps do not apply unless they convert to a C-corp and issue new shares.
The shares sold must be part of the initial offering, usually the realm of founders and early investors, or shares received through options and issued directly from the company. Stock purchased on the secondary market does not qualify because it was not issued directly by the corporation.
At issuance, the company’s gross assets cannot exceed $50 million. Once the company crosses that threshold, newly issued stock will not qualify. Timing is critical, especially for founders and early investors.
Shareholders must hold the stock for at least five years to be eligible for the maximum exclusion.
There is also an active business requirement, meaning that 80% of the company’s assets must be used in an active trade or business. The caveat here is that startups holding large reserves may exceed the threshold, so this must be monitored if QSBS is a priority.
Though these rules sound pretty straightforward, if they conflict with the corporate structure, equity grants, or startup financing, it may become complicated.
Life Sciences are Well Positioned to Qualify for QSBS
In a sector dominated by VC, many startups choose a C-corp structure preemptively to pursue that avenue.
Second, since R&D is often the main focus of life sciences organizations, those activities typically satisfy the active business requirement.
Third, long timelines during development, clinical trials, and regulatory approvals typically exceed the five-year holding period.
When you factor in all these components, the QSBS can become pivotal, not just for founders, but for potential investors and VCs, who will likely consider this to be an advantage.
Founders Can Benefit from Strategic Planning
If QSBS is a priority, early strategic planning is recommended. Eligibility for the exclusion hinges largely on decisions made in the company’s early stages, so the rules should be considered and weighed against other options.
For example, launching as a C-corp rather than an LLC would be more advantageous, as converting later may exclude founders and early investors from QSBS qualification.
As with most things in life and taxes, timing is everything. Shares issued when the company’s assets are minimal are more likely to qualify under the $50 million threshold. The holding period also starts early, helping founders maximize their assets.
Employees who received stock options also need to be mindful of the timing, as they may want to exercise their options and receive the stock before the holding period begins.
As for recordkeeping, companies must keep meticulous records of stock issuances, along with corporate activities (to satisfy the business activity requirement) and asset levels (to ensure they don’t exceed the $50 million threshold). Should QSBS eligibility ever come into question, these documents will be essential to support the review.
Common 1202 Pitfalls
Qualifying for the QSBS can mean a significant tax break, but it’s easy to get tripped up by various mitigating factors. Good planning and recordkeeping can help to ensure a positive outcome and prevent unqualified filings and the inevitable reviews that follow.
Here are a few things to avoid if QSBS is a priority:
Not meeting the five-year holding period.
Corporate buybacks within a short window (also known as the anti-churning rule) will make the affected stock ineligible.
Delayed C-corp structuring means that stock issued before the conversion is ineligible for conversion. Only stock issued after the C-corp is established qualifies.
Unexpected asset growth, such as a sudden influx of VC investment, may push the company’s gross assets above the $50 million threshold, making stock issued after these funding rounds ineligible.
Should the company be acquired before the holding period is up, shareholders may not qualify for QSBS.
Lastly, it is wise to be aware of the state-level treatment of QSBS. While some states mirror federal rules, others do not recognize the QSBS at all. Working with a qualified life sciences tax professional can help you navigate these complexities and ensure you’re on the right side of state and federal tax codes.
Ultimately, the QSBS has great potential value for founders and early-stage investors. Should the company grow through venture funding, push a product through the clinic, and sell to a large company, those initial shares could translate to up to $10 million in capital gains exclusions and millions of dollars in tax savings; all in all, something to shoot for.
The Bottom Line on 1202 (QSBS)
If certain requirements are met, QSBS can yield significant tax savings for life sciences founders. Understanding the rules is essential, and the best way to ensure you’re positioned to take advantage of the benefit is to work with an experienced tax professional.
Speak to a Growise expert today, and let’s set you up for success.